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Abstract
As a reported agonist,
11C-CUMI-101 is believed to selectively bind the G-protein-coupled state of the serotonin-1A (5-
HT1A) receptor, thereby providing a measure of the active subset of all 5-HT1A receptors in brain. Although
11C-CUMI-101
has been successfully used to quantify 5-HT1A receptors in human and monkey brain, its radiation exposure has not
previously been reported. The purpose of this study was to calculate the radiation exposure to organs of the body based
on serial whole-body imaging with positron emission tomography (PET) in human subjects.
Methods: Nine healthy volunteers were injected with 428684 MBq (mean 6 SD)
11C-CUMI-101 and then imaged with a
PET-only device for two hours from head to mid-thigh. Eleven source organs (brain, heart, liver, pancreas, stomach, spleen,
lungs, kidneys, lumbar spine L1-5, thyroid, and urinary bladder) were identified on whole body images and used to
calculate radiation doses using the software program OLINDA/EXM 1.1. To confirm that we had correctly identified the
pancreas, a tenth subject was imaged on a PET/CT device.
Results: Brain had high uptake (,11% of injected activity (IA)) at 10 min. Although liver had the highest uptake (,35% IA at
120 min), excretion of this activity was not visible in gall bladder or intestine during the scanning session. Organs which
received the highest doses (microSv/MBq) were pancreas (32.0), liver (18.4), and spleen (14.5). The effective dose of
11C-
CUMI-101 was 5.360.5 microSv/MBq.
Conclusion: The peak brain uptake (,11% IA) of
11C-CUMI-101 is the highest among more than twenty
11C-labeled ligands
reported in the literature and provides good counting statistics from relatively low injected activities. Similar to that of other
11C-labeled ligands for brain imaging, the effective dose of
11C-CUMI-101 is 5.360.5 microSv/MBq, a value that can now be
used to estimate the radiation risks in future research studies.
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Introduction
For G-protein-coupled receptors, antagonists generally bind
with equal affinity to the coupled and uncoupled states, but
agonists bind preferentially to the coupled, or active, state of the
receptor [1]. Thus, agonist radioligands have the advantage of
selectively measuring the subset of receptors that are in the active
state [2]. For example, agonist radioligands for the dopamine D2
receptor have been used to assess the effects of stimulant-induced
dopamine release [3] and agonist-induced internalization of the
receptor [4]. The first agonist radioligand introduced for studying
a serotonin receptor in human brain with PET (positron emission
tomography) was CUMI-101: [O-methyl-
11C]2-(4-(4-(2-methoxy-
phenyl)piperazine-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione)
[ 5 ] .C U M I - 1 0 1i sap a r t i a la g o n i s ta t5 - H T 1A receptors based on its
actions on adenylate cyclase and its action on binding of [
35S]GTPcS
binding to cultured cells with the human receptor [5]. CUMI-101 is
reported to be selective for 5-HT1A receptor with an inhibition
constant (Ki) of 0.15 nM [5]. In comparison, CUMI-101 binds
with much lower affinity to other receptors, such as alpha1
(Ki=6.75 nM) and 5-HT7 (Ki=12.9 nM), which correspond to
45 and 86 times lower affinity, respectively, than for the 5-HT1A
receptor. The uptake of
11C-CUMI-101 in monkey brain
matches the distribution of 5-HT1A receptors and can be
displaced by 5-HT1A receptor-specific ligands [5,6]. Finally, the
uptake of
11C-CUMI-101 in human brain has recently been
quantified relative to serial concentrations of the radioligand in
arterial plasma using compartmental modeling [7,8]
Based on these recently published studies,
11C-CUMI-101 is a
promising agonist radioligand to quantify the active state of 5-
HT1A receptors in neuropsychiatric disorders. However, the
dosimetry of
11C-CUMI-101 has not been reported, and this
information is typically required for research studies in human
subjects. The purpose of this study was to calculate the radiation
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25309exposure of
11C-CUMI-101 to organs of the body based on whole-
body imaging in healthy volunteers.
Materials and Methods
Radiopharmaceutical Preparation
11C-CUMI-101 was synthesized as described in our Investiga-
tional New Drug Application #107,916 (http://pdsp.med.unc.
edu/snidd/). In brief, O-desmethyl-CUMI-101 (Alpha Biophar-
maceuticals, Burlingame, Pennsylvania, USA) was treated with
11C-iodomethane. The generated [
11C]CUMI-101 was separated
with reverse phase high-performance liquid chromatography and
obtained with a radiochemical purity greater than 99%. Specific
activity at time of injection was 86.4624.1 GBq/micromol.
Human Subjects
We obtained verbal and written informed consent from all
subjects in this study.
The participants in this study were nine healthy volunteers: five
males and four females, age 36612.3 years, weight 89.5616.5 kg,
and BMI 29.663.6 (mean 6 SD). All subjects were medically and
psychiatrically healthy, based on history, Structured Clinical
Interview for DSM Disorders – Non-patient, physical examina-
tion, EKG, urine toxicology, urinalysis, and blood testing
(complete metabolic profile, complete blood count with differen-
tial, thyroid stimulating hormone, RPR, HIV, and hepatitis A, B
and C antibody testing). The Radiation Safety Committee of the
National Institutes of Health and the Combined Neurosciences
(CNS) Institutional Review Board of the National Institute of
Mental Health approved our ethical use of
11C-CUMI-101 in this
study of human subjects.
PET Scan Procedures
We followed the procedure for image acquisition and
reconstruction described previously by our group, using GE
Advance [9]. In brief, we acquired a 21-min transmission scan
(3 min at each of the 7 body segments) using rotating
68Ge rods for
subsequent attenuation correction. We then administered
428684 MBq (range 380 to 585 MBq) of
11C-CUMI-101
intravenously over 60 seconds using a PHD 2000 syringe pump.
We acquired 2D dynamic emission scans consisting of 14 cycles.
Acquisition cycles started with an emission scan at the first bed
position (i.e., the head) and continued by moving the bed distally
for a total of 7 segments. Upon completion of the seventh cycle,
the bed was moved back to the original position with the head in
the scanner. The 14 cycles increased in duration as follows:
460.25, 360.5, 361, 362, and 164 min (number of cycles6dura-
tion per bed position during that cycle). Movements of the bed
between bed positions required 3 s each, and repositioning from
thigh back to head at the completion of each of the cycle required
13 s. In total, the emission scan was 120 minutes. All PET images
were reconstructed with ordered subset expectation maximization
image reconstruction and were corrected for attenuation and
scatter. PET images were reconstructed with ordered subset
expectation maximization image reconstruction in 28 subsets with
four iterations and were corrected for attenuation. All subjects
were monitored for safety by checking blood (complete blood
count with differential, complete metabolic profile, thyroid
stimulating hormone) and urine (urinalysis) within 24 hours before
and after the PET scan. Blood pressure and EKG were obtained
prior to tracer injection and at 15, 30, and 60 min after injection.
To decrease movement during the scan, straps with Velcro
adhesive were firmly wrapped around the subject’s torso and
attached to the bed.
For the PET/CT scan on aSiemens Biograph
TM mCT, we
obtained a scout image and full body CT (from head to upper
thigh) using a frequency of 115 mA. We then administered
369 MBq of
11C-CUMI-101 intravenously over 60 seconds using
a PHD 2000 syringe pump. We waited 10 minutes to allow
radioligand to perfuse the body and bind to receptors in source
organs. We then started one cycle of 2D emission scans for each of
7 bed positions, starting with the head. The duration per bed
position was 5 minutes long. Thus, we imaged the pancreas at
approximately 30 minutes after injection of
11C-CUMI-101.
Additional Monitoring of Human Subjects
Additional monitoring of human subjects was prompted by
toxicology studies in rats. For details, see our IND application
(http://pdsp.med.unc.edu/snidd/). In brief, rats receiving
1,000 times the human equivalent dose of CUMI-101, had
elevated plasma creatinine kinase (CK) in three of ten males
a n dn o n eo ft e nf e m a l e s .N o n eo ft h er a t sw i t he l e v a t e dC K
died prematurely, and none demonstrated seizures or other
physical findings that might be associated with elevated CK.
Because of these results, we were required by FDA to monitor
subjects with weekly blood draws (CK, MB fraction, troponin I,
AST, ALT, and ammonia) for four consecutive weeks after
injection of
11C-CUMI-101.
Analysis of PET Images
For each subject, source organs were identified on the individual
slices from the PET image averaged over the entire two-hour
scanning period using PMOD 3.0 software (PMOD Technologies,
Zurich, Switzerland). Brain, salivary glands (parotid and subman-
dibular glands), heart, liver, pancreas, stomach, and spleen were
identified in the axial images. Lungs, kidneys, lumbar spine (L1-5),
thyroid, and urinary bladder were identified in the coronal
direction. Lumbar vertebrae were used to estimate uptake in red
marrow, since they contain ,12.3% of all red marrow in an adult
[10]. We used generous-sized regions to encompass all radioac-
tivity from each source organ. Nevertheless, whole body images
were viewed with all regions loaded to assure no overlap.
Uptake in each organ was corrected for recovery of measured
activity, which was calculated from a large region of interest
placed over the entire body for each of the 14 frames. Recovery
averaged 90% for all frames. The ‘‘remainder of body’’ was
calculated for each time point as the decayed value of the original
injected activity minus that present in the identified source organs.
Residence Time Calculations
At each time point, the measured activity (i.e., not corrected
for decay) of the source organ was expressed as a percentage of
the injected activity (%IA). The area under the time-activity
curve of each organ was calculated by the trapezoidal method
during the 120-min scanning session. The area after the last
image to infinity was calculated by assuming that the subsequent
decline of radioactivity occurred by only physical decay, without
any further biological clearance. The area under the curve of
%IA from time zero to infinity equals residence time of the organ.
The residence time for the lumbar vertebrae was multiplied by a
weighting factor (8.13=100% / 12.3%) to represent total red
marrow in the body. To calculate the residence time for
remainder of body, the residence times for all source organs
were summed and subtracted from the fixed theoretical value of
T1/2/ln 2=0.49 h.
The software program OLINDA/EXM 1.1 [11] was used to
calculate radiation equivalent doses according to the Medical
Internal Radiation Dose scheme, using the 70-kg adult male
Dosimetry of
11C-CUMI-101
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source organ, we included activity in salivary glands to remainder
of body.
Results
Pharmacological Effects
Subjects received an injected chemical dose of 5.061.0 nmol
11C-CUMI-101. This dose caused no pharmacological effects in
any subject during the two-hour PET scan, based on patient
reports, blood pressure, pulse, temperature, respiratory rate, and
EKG.
Because 1,000 times the human equivalent dose of nonradio-
active CUMI-101 caused elevated plasma CK in some rats (see
Methods), the FDA required us to monitor subjects once per week
for four weeks after the PET scan. All subjects were interviewed in
person, and blood was drawn to measure CK, CKMB, Troponin
I, AST, ALT, and ammonia. The plasma CK was transiently
elevated in three of the nine subjects at one to four weeks after
injection of
11C-CUMI-101. Although these three subjects
reported no symptoms, the peak elevations were high: about
900, 1,800, and 2,000 mg/dL, with the normal range being 38–
386 mg/dL. After consultations with internists and cardiologists,
we interpret theses changes in plasma CK as clinically non-
significant, not related to the injection of
11C-CUMI-101, but
likely caused by vigorous exercise, dehydration, and/or blunt
trauma to muscles.
For four weeks after the injection of
11C-CUMI-101, all troponin
IvalueswerenormalandCKMBwasnevergreaterthan5%oftotal
CK. Ammonia was mildly elevated in 15% of blood draws but was
never higher than 52 micromol/L. Further, the mild elevations in
Figure 1. Biodistribution of radioactivity in a female healthy
volunteer after injecting
11C-CUMI-101 (585 MBq). The high
activity at 18 min in the upper left quadrant and adjacent to the liver
was thought to be stomach. These planar images are compressed in the
coronal direction at the specified times. The right side of the person is
on the left side of the image.
doi:10.1371/journal.pone.0025309.g001
Figure 2. Time-activity curves for identifiable organs after injection of
11C-CUMI-101. A: Liver (N), Brain (n), and Lungs (&). B: Pancreas
(N), Stomach (n), and Spleen (&). C: Kidneys (N), Urinary Bladder (n), and Heart (&). D: Bone Marrow (N), Salivary Glands (n), and Thyroid (&). Data
are the average determined in nine healthy volunteers and are corrected for radioactive decay. SD bars are not included to avoid cluttering the graph,
but coefficient of variance is reported for residence time, which reflects the area under these time-activity curves (Table 2).
doi:10.1371/journal.pone.0025309.g002
Dosimetry of
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the specimens, which should remain on ice for valid measurements.
AST was normal throughout all draws. ALT was elevated once in
one subject at the 2 week mark, but to only 5% above the normal
upper limit, and this subject reported no complaints.
Biodistribution
The whole body images were notable for early distribution in
the blood pool, accumulation in the target organ (i.e., brain), and
apparent metabolism in the liver (Fig. 1). At early time points,
radioactivity was prominent in organs with high blood volume,
including kidneys, heart, lung, and thyroid (Figure 2). Consistent
with its high density of 5-HT1A receptors, the brain had high
uptake of radioactivity, with a peak of about 11% IA at 10 min
after injection of
11C-CUMI-101. This peak brain uptake of 11%
IA is high relative to more than 20 other radioligands used for
brain imaging: 4.563.0, with range of 0.03 to 11 (Table S1). Liver
continuously accumulated radioactivity and reached about 35%
IA by the end of the scan. Although the high uptake in liver likely
represented radiometabolites, we saw no evidence of hepatobiliary
excretion during the two-hour scanning period. That is, we saw no
significant radioactivity in gall bladder or small intestine.
Furthermore, we saw no evidence of significant urinary excretion,
since the urinary bladder had on average less than 2% IA at two
hours. Because we could not identify the routes of excreting
radioactivity, we applied neither the gastrointestinal nor the
dynamic urinary bladder models to calculate dosimetry.
A PET/CT scan in a tenth subject confirmed that we had
correctly identified the pancreas as an abdominal organ with
relatively high uptake of radioactivity (Fig. 3).
Dosimetry
If all
11C radioactivity remains within the body (i.e., none is
excreted), the total residence time equals 0.49 h. Of this total
residence time, we attributed about half to eleven source organs
and half to remainder of body (Table 1). The mean effective dose
derived from nine healthy volunteers was 5.360.5 microSv/MBq
(19.562.2 mrem/mCi). This effective dose (microSv/MBq) is
similar to that of 33 other
11C-radioligands used for brain imaging,
where the mean effective dose was 5.562.0, with range of 3.0 to
16.0 (Table S1). Thus, injection of 370 MBq
11C-CUMI-101 for a
brain study would cause an effective dose of 2.060.2 mSv
(0.2060.02 rem). The three organs that received the highest
radiation exposure were: pancreas 32.0612.1 microSv/MBq,
liver 18.463.1 mSv/MBq, and spleen 14.566.9 microSv/MBq.
Discussion
Because
11C-CUMI-101 is a promising agonist radioligand to
image 5-HT1A receptors in brain, we calculated the radiation
exposure to organs of the body from whole body images acquired
in nine healthy volunteers for two hours after injection of the
radioligand. As a measure of exposure to the entire body and
weighted for sensitivity to radiation damage, the effective dose was
5.360.5 microSv/MBq (19.562.2 mrem/mCi), which is compa-
rable to other
11C-labeled ligands for brain imaging (Table S1).
Thus, injection of 370 MBq
11C-CUMI-101 would yield an
effective dose of 2.0 mSv, which is well below the commonly used
limit of 10 mSv for research studies with minor to intermediate
levels of risk (ICRP 62).
The biodistribution of radioactivity after injection of
11C-
CUMI-101 was notable for high uptake in three organs: brain,
liver, and pancreas. Maximal uptake in brain was about 11% IA
and occurred at 5–10 min post injection.
We expected substantial brain uptake high because of the high
affinity of the radioligand (Ki=0.15 nM) and the moderately high
Figure 3. PET-CT of abdomen at approximately 30 minutes after injection of
11C-CUMI-101 (369 MBq) shows high uptake in
pancreas. A: Axial CT of abdomen, with right side of subject on left, and anterior aspect facing upward on page. B: PET image of same cross-section,
showing high uptake of
11C-CUMI-101 in pancreas and liver. C: Fused PET-CT image confirms that radioactive signal on the left is at anatomical
location of pancreas (pink arrow).
doi:10.1371/journal.pone.0025309.g003
Table 1. Residence times of source organs and remainder of
body determined in nine healthy volunteers.
Organ
Residence Time (h)
Mean ± SD COV (%)
Liver 0.104460.0189 18%
Brain 0.044260.0094 21%
Red marrow 0.030560.0088 29%
Lungs 0.028560.0191 67%
Pancreas 0.011060.0046 42%
Kidneys 0.008960.0021 24%
Spleen 0.008860.0047 54%
Stomach 0.006060.0035 58%
Heart wall 0.005260.0018 36%
Urinary bladder 0.002260.0030 134%
B
Salivary glands 0.000960.0005 52%
C
Thyroid 0.000360.0001 43%
Remainder of body 0.240560.0177 7%
Total
A 0.4900
AIf all radioactivity remains in the body, the sum of all residence times equals
0.49 h for
11C.
BAlthough this variance was high as a percentage, the mean residence time of
the urinary bladder was itself quite small. The small residence time
corresponded to accumulation of urinary activity of ,2% IA by end of scan
(Fig. 2).
CSalivary glands included parotid and submandibular glands. We list the
residence time here for comparison with source organs. However, because
OLINDA/EXM1.1 excludes salivary glands as a source organ, we attributed
activity from salivary glands to remainder of body.
doi:10.1371/journal.pone.0025309.t001
Dosimetry of
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were surprised by the magnitude of peak brain uptake (11% IA),
which is the highest among 24
11C-labeled radioligands with
reported values of peak brain uptake (Table S1). Since peak brain
uptake occurred early (10 min) and at a time of relatively little
binding to receptors, we suspect that physicochemical properties of
the radioligand (e.g., optimal lipophilicity) and blood flow were
significant factors in the high brain uptake of
11C-CUMI-101.
Among all organs, the liver had the highest uptake of radioactivity,
about 35% IA at two hours. Although this radioactivity
presumably represented radiometabolites, we saw no evidence of
excretion via gall bladder or small intestine during the two hours of
scanning. High uptake of radioactivity in liver and brain caused
these two organs to have among the highest radiation exposures
(mSv/MBq): liver 18.463.1 and brain 10.462.1. The third organ
with unusually high uptake was the pancreas. In fact, we
performed a PET/CT scan in a tenth subject to confirm its
identity. We do not know why the pancreas had such high uptake,
because this organ is not known to have high densities of 5-HT1A
receptors. Furthermore, the radioactivity in pancreas could derive
not from CUMI-101 but from a metabolite that has affinity for
proteins involved in either the endocrine or exocrine functions of
the pancreas.
Because some rats in the animal toxicology study developed
elevated plasma concentrations of a muscle enzyme (CK), we
monitored subjects weekly for four weeks for evidence of muscle
damage. Three of the nine subjects had transiently elevated
plasma CK at one to four weeks after injection of
11C-CUMI-101.
These elevations in CK were asymptomatic and did not impair
renal function. We think plasma CK was elevated as a result of
intense exercise, dehydration, and/or muscle injury. In retrospect,
we recommend that plasma CK not be used to monitor toxicity in
subjects who regularly exercise, and we question the utility of
monitoring subjects for so long (four weeks) after injection of tracer
pharmacological dose of a drug.
In conclusion, based on biodistribution studies in healthy
volunteers, the effective dose of
11C-CUMI-101 is 5.360.5 mi-
croSv/MBq (19.562.2 mrem/mCi), which is comparable to other
11C-labeled ligands for brain imaging. This value can now be used
to guide the maximal injected activity in future research studies
and to advise subjects of the radiation risks associated with
11C-
CUMI-101.
Supporting Information
Table S1 The effective dose for
11C-CUMI-101 was
5.3±0.5 microSv/MBq (19.5±2.2 mrem/mCi), which is
comparable to other
11C-labeled ligands for brain
imaging. Among 33 other
11C-radioligands used for brain
imaging, the mean effective dose was 5.562.0, with range of 3.0 to
16.0. The peak brain uptake for
11C-CUMI-101 was 11% injected
activity (IA), the highest relative to more than 20 other
radioligands used for brain imaging.
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